Amgen, announced the appointment of Malay Naik, as Executive Director, US Brand Lead – Oncology at, marking a new step in his career within the pharmaceutical industry. Naik shared the move by announcing the beginning of his new position at the biotechnology company.
Naik brings a background in pharmaceutical marketing, commercial strategy and oncology. His professional experience has included roles focused on brand strategy and healthcare markets, supported by his Doctor of Pharmacy education from Rutgers University. His career has also involved leadership and marketing responsibilities within the pharmaceutical sector.
The new position comes at a time when oncology remains a highly competitive and rapidly evolving area of the life sciences industry. Pharmaceutical companies are managing increasingly complex treatment landscapes while working to communicate the clinical value of therapies to healthcare professionals and patients.
Also Read: HCLTech Appoints Dr. Himanshu Tagra as Senior Vice President
For brand leaders, this environment requires a combination of commercial understanding, knowledge of the healthcare ecosystem and the ability to translate scientific developments into clear market strategies. The role also sits at the intersection of medical innovation, patient needs and changing expectations around healthcare delivery.
Naik’s move to Amgen highlights the continued importance of specialized commercial leadership within oncology. As pharmaceutical companies expand their portfolios and navigate evolving treatment options, experienced professionals with knowledge of both healthcare and brand strategy remain an important part of commercial decision-making.
